Abstract
PGE2, an essential homeostatic factor, is also a key mediator of immunopathology in chronic infections and cancer. The impact of PGE2 reflects the balance between its cyclooxygenase 2-regulated synthesis and 15-hydroxyprostaglandin dehydrogenase-driven degradation and the pattern of expression of PGE2 receptors. PGE2 enhances its own production but suppresses acute inflammatory mediators, resulting in its predominance at late/chronic stages of immunity. PGE2 supports activation of dendritic cells but suppresses their ability to attract naive, memory, and effector T cells. PGE2 selectively suppresses effector functions of macrophages and neutrophils and the Th1-, CTL-, and NK cell-mediated type 1 immunity, but it promotes Th2, Th17, and regulatory T cell responses. PGE2 modulates chemokine production, inhibiting the attraction of proinflammatory cells while enhancing local accumulation of regulatory T cells cells and myeloid-derived suppressor cells. Targeting the production, degradation, and responsiveness to PGE2 provides tools to modulate the patterns of immunity in a wide range of diseases, from autoimmunity to cancer.
Footnotes
This work was supported by National Institutes of Health Grants 1PO1CA132714 and 1P50CA121973.
Abbreviations used in this article:
- AA
- arachidonic acid
- COX
- cyclooxygenase
- DC
- dendritic cell
- MDSC
- myeloid-derived suppressor cell
- 15-PGDH
- 15-hydroxyprostaglandin dehydrogenase
- Treg
- regulatory T cell.
- Received September 19, 2011.
- Accepted November 3, 2011.
- Copyright © 2011 by The American Association of Immunologists, Inc.